---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-023644"
form_type: "8-K"
ticker: "PDSB"
cik: "0001472091"
company_name: "PDS Biotechnology Corp"
filed_at: "2025-06-25T23:59:59+00:00"
generated_at: "2026-05-18T19:14:45.730131+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "low"
source: SEC EDGAR
---

# PDS Biotechnology updates corporate presentation; no financial or clinical data disclosed

## Summary
- Filed 8-K on June 25, 2025, with updated corporate presentation as Exhibit 99.1.
- Presentation titled 'Addressing the Growing Incidence of HPV16-Related Cancers' and 'Precision Designed Science For Immunotherapy'.
- No new financial results, clinical trial data, or guidance provided in the filing.

## SEC filing metadata
- accession: 0001140361-25-023644
- form_type: 8-K
- ticker: PDSB
- cik: 0001472091
- company_name: PDS Biotechnology Corp
- filed_at: 2025-06-25T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: low
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472091/000114036125023644/0001140361-25-023644-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472091/000114036125023644/ef20051058_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-023644
- JSON: https://secwatch.observer/filing/0001140361-25-023644.json
- Plain text: https://secwatch.observer/filing/0001140361-25-023644.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.